NCT07106034View on ClinicalTrials.gov

Standard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II Trial

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2027

Conditions
Advanced Colorectal Cancer
Interventions
DRUG

Ongericimab + Toripalimab + Bevacizumab + FOLFOX

Ongericimab, Toripalimab, Bevacizumab, Oxaliplatin, Calcium folinate, 5-FU, Q2W

DRUG

Ongericimab + Toripalimab + Bevacizumab + FOLFIRI

Ongericimab, Toripalimab, Bevacizumab, Irinotecan, Calcium folinate, 5-FU, Q2W

Trial Locations (1)

201399

Shanghai Pudong Hospital, Shanghai

All Listed Sponsors
collaborator

Shanghai Junshi Bioscience Co., Ltd.

OTHER

lead

Shanghai Pudong Hospital

OTHER